Cannabinoid Encyclopedia

Focused research review

Does CBD help with pain?

CBD has not reduced pain reliably across controlled human studies. A few trials report improvement, but the answer changes sharply with route, dose, pain condition, and formulation.

Updated July 2026 15 research sources Human research included

The short answer

What is the bottom line?

CBD does not have a reliable, general pain-relief result across controlled human trials. Two studies reported improvement: a small topical peripheral-neuropathy trial and a newer oral trial using CBD up to 800 mg per day after spinal cord injury. 2 1

Several other placebo-controlled studies did not detect a CBD benefit for chronic neuropathic pain, pain or spasticity in multiple sclerosis or spinal cord injury, quality of life, or experimental pain responses in fibromyalgia. 3 4 6

A CBD-enriched extract trial in recurrent endometriosis pain also found no advantage over placebo for mean pain or responder rates and reported more mild adverse events. Because it tested an extract, it cannot answer the isolated-CBD question by itself. 5

What this means: CBD may help some pain conditions or formulations, but the present human evidence is mixed and mostly negative for a broad claim that CBD reliably relieves pain. Topical CBD, high-dose oral CBD, CBD-dominant cannabis, and enriched extracts should be read as separate interventions. 2 1 3 4 6

How to read this answer: Research has examined CBD and pain. This page brings together 8 human-study sources and 7 research reviews. It includes 16 specific study findings from 6 sources. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBD and pain.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Controlled oral CBD studies are mostly null, although a topical trial and one high-dose oral trial reported improvement. 1

  2. 2

    Pain type, route, dose, and formulation change the question; CBD-only results should not be blended with THC/CBD medicines. 2

  3. 3

    The current evidence does not support a broad statement that CBD reliably relieves pain. 3

Choose your question

What kind of pain question are you asking?

Pain is not one outcome. Separate the pain condition, route, dose, and formulation before comparing results.

  1. 01Reader question

    Where did CBD reduce pain?

    See the topical-neuropathy and high-dose spinal-cord-injury signals.

    See the evidence
  2. 02Reader question

    Where did CBD not help?

    Compare the controlled oral and CBD-dominant cannabis trials that did not beat placebo.

    See the evidence
  3. 03Reader question

    Does topical CBD answer the oral-CBD question?

    No. Route and delivered dose can change exposure and cannot be assumed equivalent.

    See the evidence
  4. 04Reader question

    What about extracts or THC/CBD products?

    Keep enriched extracts and mixed-cannabinoid medicines separate from isolated CBD.

    See the evidence

Research areas

What researchers studied about CBD and pain

The most useful comparison is not simply positive versus negative. It is which pain condition, product, route, and dose produced each result.

Positive signal

Topical peripheral neuropathy

A small topical-oil trial reported less intense and sharp pain plus fewer cold and itchy sensations, but the applied CBD dose was not stated. 2

Positive signal

High-dose oral CBD after spinal cord injury

A crossover trial reported a modest pain-intensity reduction with oral CBD titrated up to 800 mg per day. 1

No detected benefit

Other neuropathic-pain trials

Controlled CBD-only studies using lower oral doses did not improve pain, spasticity, global change, or quality of life versus placebo. 3 4

Different formulation

CBD-dominant cannabis and enriched extracts

A CBD-dominant cannabis experiment and a CBD-enriched endometriosis extract trial did not detect a pain benefit over placebo. 6 5

Study-by-study results

What did the CBD pain studies report?

Each result-bearing study appears once with its outcomes, formulation, dose, duration, comparator, limitations, and PubMed source kept together.

01

Where did CBD reduce pain?

Two controlled studies reported improvement, but one tested a topical oil and the other used oral CBD up to 800 mg per day.

Study details

Topical peripheral-neuropathy trial

PubMed 31793418
Study type
randomized placebo-controlled crossover trial
Population
29 adults with symptomatic peripheral neuropathy of the lower extremities
Formulation
topical oil containing 250 mg CBD per 3 fluid ounces
Dose
250 mg CBD per 3 fluid ounces; applied dose not stated in the abstract
Duration
4 weeks before crossover
Comparator
placebo

Measured outcomes

Improvement reported

intense neuropathic pain

The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided. 2

Improvement reported

sharp neuropathic pain

The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided. 2

Improvement reported

cold sensations associated with peripheral neuropathy

The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided. 2

Improvement reported

itchy sensations associated with peripheral neuropathy

The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided. 2

Keep in mind: The trial enrolled 29 participants, with 15 initially assigned to CBD and 14 to placebo. The applied amount and resulting CBD dose were not stated in the abstract. The abstract reported significance but did not provide effect estimates or P values.

Study details

High-dose spinal-cord-injury trial

PubMed 42256679
Study type
randomized double-blind placebo-controlled crossover clinical trial
Population
38 adults with spinal cord injury and chronic neuropathic pain in the primary analysis
Formulation
oral CBD
Dose
up to 800 mg/day
Duration
two 6-week treatment periods separated by a 4-week washout
Comparator
placebo

Measured outcomes

Improvement reported

neuropathic pain intensity after spinal cord injury

Active-phase mean 3.82 (SEM 0.23); mean difference versus placebo -0.54 (SEM 0.15; 95% CI -0.88 to -0.21; P<0.001). 1

Keep in mind: The modified intention-to-treat analysis included 38 participants. The trial concerned neuropathic pain after spinal cord injury and may not generalize to other pain conditions. CBD was titrated to a high dose of up to 800 mg and day.

02

Where did CBD not beat placebo?

Several controlled studies found no CBD advantage for neuropathic pain, spasticity, quality of life, or experimental pain responses.

Study details

Oral peripheral-neuropathic-pain trial

PubMed 36571471
Study type
randomized double-blind placebo-controlled four-arm trial
Population
115 patients in the intention-to-treat analysis with peripheral neuropathic pain after failure of at least one evidence-based treatment
Formulation
oral CBD capsules
Dose
flexible dosing from 5 to 50 mg
Duration
8 weeks
Comparator
placebo

Measured outcomes

No difference detected

weekly average peripheral neuropathic pain

CBD did not reduce pain versus placebo; week-8 CBD effect estimate 1.14 NRS points worse (95% CI 0.11 to 2.19). 3

Keep in mind: The trial included separate CBD, THC, CBD and THC, and placebo arms; this finding concerns the CBD-only arm. Participants had peripheral neuropathic pain that had not responded to at least one previous evidence-based treatment. The CBD dose was flexible from 5 to 50 mg.

Study details

MS and spinal-cord-injury pain trial

PubMed 37630995
Study type
multicenter randomized double-blind placebo-controlled four-arm trial
Population
134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and/or spasticity
Formulation
CBD; formulation details not stated in the PubMed abstract
Dose
up to 45 mg/day
Duration
6 weeks followed by a 1-week phaseout
Comparator
placebo

Measured outcomes

No difference detected

neuropathic pain intensity in multiple sclerosis or spinal cord injury

CBD-versus-placebo estimate 0.45 (95% CI -0.47 to 1.38); no significant difference. 4

No difference detected

spasticity intensity in multiple sclerosis or spinal cord injury

CBD-versus-placebo estimate 0.46 (95% CI -0.74 to 1.65); no significant difference. 4

No difference detected

patient global impression of change

The abstract reports no significant active-treatment versus placebo difference; no CBD-specific estimate is provided. 4

No difference detected

quality of life

The abstract reports no significant active-treatment versus placebo difference; no CBD-specific estimate is provided. 4

Keep in mind: The trial included separate THC, CBD, THC and CBD, and placebo arms; this finding concerns the CBD-only arm. The trial randomized 134 of a planned 448 participants after recruitment challenges. The population combined multiple sclerosis and spinal cord injury.

Study details

CBD-dominant fibromyalgia experiment

PubMed 30585986
Study type
randomized placebo-controlled four-way crossover experimental trial
Population
20 adults with fibromyalgia and chronic pain
Formulation
CBD-dominant cannabis containing 18.4 mg CBD and less than 1 mg THC
Dose
18.4 mg CBD and less than 1 mg THC once
Duration
3-hour laboratory assessment after one inhalation
Comparator
cannabinoid-free placebo cannabis

Measured outcomes

No difference detected

spontaneous pain response after CBD-dominant cannabis

No treatment, including the CBD-dominant variety, produced a greater effect than placebo on spontaneous pain. 6

No difference detected

electrical pain response after CBD-dominant cannabis

No treatment, including the CBD-dominant variety, produced a greater effect than placebo on electrical pain. 6

Keep in mind: The intervention was CBD-dominant cannabis with less than 1 mg THC, not isolated CBD. The experimental crossover trial included 20 participants and assessed one inhalation over three hours. The finding may not generalize to longer-term treatment or other routes and formulations.

03

What changes when the product is an extract?

A CBD-enriched endometriosis extract did not improve pain more than placebo and caused more mild adverse events.

Study details

Endometriosis CBD-enriched-extract trial

PubMed 42261989
Study type
single-centre randomized triple-blind placebo-controlled parallel trial
Population
102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms
Formulation
cannabidiol-enriched extract oil (CBDO)
Dose
escalated from 10 mg/day to 150 mg/day, then tapered
Duration
10 weeks
Comparator
placebo

Measured outcomes

No difference detected

mean recurrent endometriosis pain intensity

End-of-treatment mean pain was 41.6 mm with CBDO and 36.8 mm with placebo; the between-group difference was not significant. 5

No difference detected

rate of at least 30% endometriosis pain reduction

Approximately 60% in both groups reported at least 30% improvement; between-group differences were not significant. 5

No difference detected

rate of at least 50% endometriosis pain reduction

Approximately 40% in both groups achieved at least 50% pain reduction; between-group differences were not significant. 5

Safety or tolerability finding

mild adverse-event frequency

The abstract reports more mild adverse events with CBDO, mainly gastrointestinal symptoms and perceived weight changes; counts and P values are not provided. 5

Keep in mind: The intervention was a cannabidiol-enriched extract oil, so the result should not be treated as evidence about isolated CBD. The trial was stopped at a planned interim analysis for lack of a clinically relevant primary-outcome benefit and more mild adverse events. All participants had surgically confirmed endometriosis, recurrent symptoms, and ongoing hormonal therapy.

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

8 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

7 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

Not prominent

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CBD and pain is not one kind of study. This source set includes 8 clinical studies in people, 5 systematic reviews or meta-analyses, and 2 narrative or expert reviews. 3

The recorded populations or models include people or patients (13 sources), 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms (1 source), and 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and or or spasticity (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is pain-related outcomes (15 sources), electrical pain response (1 source), and mild adverse events (1 source). Closely related outcome names can still describe different measurements. 5

Some source records specify doses including 18.4 mg CBD and less than 1 mg THC once (1 source), 250 mg CBD per 3 fluid ounces (1 source), and escalated from 10 mg or day to 150 mg or day, then tapered (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 6

The CBD and pain source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 7

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial.

On this page, this source examines CBD and pain-related outcomes and CBD and neuropathic pain intensity after spinal cord injury. 1

Study type
clinical study in people
Population or model
people or patients and 38 adults with spinal cord injury and chronic neuropathic pain in the primary analysis
Outcome focus
pain-related outcomes and self-reported pain intensity on a 0-to-10 visual analogue scale
Dose recorded
up to 800 mg or day
Evidence stage
human research

clinical study in people

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities.

On this page, this source examines CBD and pain-related outcomes, CBD and intense neuropathic pain, and CBD and sharp neuropathic pain and other related questions. 2

Study type
clinical study in people
Population or model
people or patients and 29 adults with symptomatic peripheral neuropathy of the lower extremities
Outcome focus
pain-related outcomes and neuropathic Pain Scale intense-pain item and other recorded details
Dose recorded
250 mg CBD per 3 fluid ounces
Evidence stage
human research

clinical study in people

Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.

On this page, this source examines CBD and pain-related outcomes and CBD and weekly average peripheral neuropathic pain. 3

Study type
clinical study in people
Population or model
people or patients
Outcome focus
pain-related outcomes and weekly average daily pain on a numeric rating scale
Dose recorded
flexible dosing from 5 to 50 mg
Evidence stage
human research

clinical study in people

Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.

On this page, this source examines CBD and pain-related outcomes, CBD and neuropathic pain intensity in multiple sclerosis or spinal cord injury, and CBD and spasticity intensity in multiple sclerosis or spinal cord injury and other related questions. 4

Study type
clinical study in people
Population or model
people or patients and 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and or or spasticity
Outcome focus
pain-related outcomes and patient-reported neuropathic pain intensity and other recorded details
Dose recorded
up to 45 mg or day
Evidence stage
human research

clinical study in people

Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study.

On this page, this source examines CBD and pain-related outcomes, CBD and mean recurrent endometriosis pain intensity, and CBD and rate of at least 30% endometriosis pain reduction and other related questions. 5

Study type
clinical study in people
Population or model
people or patients and 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms
Outcome focus
pain-related outcomes and weekly average perceived pain on a visual analogue scale and other recorded details
Dose recorded
escalated from 10 mg or day to 150 mg or day, then tapered
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on CBD and pain should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 5

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Does CBD help with pain?

Sometimes, but not reliably across controlled human studies. Positive results came from a small topical trial and a high-dose oral spinal-cord-injury trial, while several other CBD studies were null. 7

Is topical CBD the same as oral CBD?

No. Route changes absorption and exposure, and the applied dose in the positive topical trial was not reported in the abstract. 8

What kinds of pain were studied?

The result-bearing studies examined peripheral neuropathy, spinal-cord-injury pain, multiple-sclerosis-related pain or spasticity, fibromyalgia, and recurrent endometriosis pain. 9

Do THC/CBD products prove that CBD alone relieves pain?

No. A mixed-cannabinoid medicine or extract answers a different formulation question from isolated CBD. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. clinical study in people; human research PubMed 42256679 DOI 10.1016/j.eclinm.2026.103986
  2. 2
    The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. clinical study in people; human research PubMed 31793418 DOI 10.2174/1389201020666191202111534
  3. 3
    Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. clinical study in people; human research PubMed 36571471 DOI 10.1002/ejp.2072
  4. 4
    Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. clinical study in people; human research PubMed 37630995 DOI 10.3390/ph16081079
  5. 5
    Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. clinical study in people; human research PubMed 42261989 DOI 10.1177/25785125251413989
  6. 6
    An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. clinical study in people; mechanism-focused research; human research PubMed 30585986 DOI 10.1097/j.pain.0000000000001464
  7. 7
    Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. systematic review or meta-analysis; evidence still limited PubMed 37648266 DOI 10.1136/bmj-2022-072348
  8. 8
    Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. systematic review or meta-analysis; evidence still limited PubMed 35510826 DOI 10.1002/14651858.cd013444.pub2
  9. 9
    Cannabis-based medicines for chronic neuropathic pain in adults. systematic review or meta-analysis; evidence still limited PubMed 29513392 DOI 10.1002/14651858.cd012182.pub2
  10. 10
    Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. systematic review or meta-analysis; evidence still limited PubMed 41429020 DOI 10.7326/annals-25-03152
  11. 11
    Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. systematic review or meta-analysis; evidence still limited PubMed 33561282 DOI 10.1093/pm/pnab050
  12. 12
    Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. clinical study in people; human research PubMed 33118602 DOI 10.1093/pm/pnaa303
See all 15 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 35510826
  2. Cannabis-based medicines for chronic neuropathic pain in adults. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 29513392
  3. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 41429020
  4. Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. clinical study in people; human research / 5 linked research notes PubMed 37630995
  5. High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. clinical study in people; human research / 2 linked research notes PubMed 42256679
  6. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33561282
  7. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. clinical study in people; human research / 5 linked research notes PubMed 31793418
  8. Cannabinoids: Medical implications. narrative or expert review; evidence still limited / 1 linked research note PubMed 26912385
  9. Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. narrative or expert review; evidence still limited / 1 linked research note PubMed 39445260
  10. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. clinical study in people; human research / 2 linked research notes PubMed 36571471
  11. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. clinical study in people; human research / 1 linked research note PubMed 18035205
  12. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 37648266
  13. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. clinical study in people; mechanism-focused research; human research / 3 linked research notes PubMed 30585986
  14. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. clinical study in people; human research / 1 linked research note PubMed 33118602
  15. Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. clinical study in people; human research / 5 linked research notes PubMed 42261989